Gene Therapy Company Sets IPO Target At $92M
The company develops gene therapy treatments for X-Linked Myotubular Myopathy, a condition that kills one in every 50,000 newborn boys by the time they're 2 years old.
San Francisco Business Times:
S.F.'s Audentes Therapeutics Sets IPO Price Targets, Hopes To Raise Up To $92M
Gene therapy company Audentes Therapeutics on Monday set a price range for a planned IPO in which it hopes to raise up to $92 million. The San Francisco company led by CEO Matthew R. Patterson first disclosed its plans to go public in January when it said it hoped to raise up to $86 million. (Schubarth, 7/11)